ArticleNature communications2024
Genomic epidemiology reveals geographical clustering of multidrug-resistant Escherichia coli ST131 associated with bacteraemia in Wales.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 13 citations in OpenAlex.
- A community-based One Health approach to the pandemic dynamics ofAntimicrobial agents and chemotherapy · 2026Article
- Building the Tools for Enhanced Waterway Surveillance: Prediction of Antimicrobial-ResistantJournal of the Royal Society of New Zealand · 2026Article
- Linking land use to the likely origins of third-generation cephalosporin-resistant Enterobacterales in freshwater.Applied and environmental microbiology · 2026Article
- Enrichment of the high-risk ST131 clone among ciprofloxacin-resistant Escherichia coli in a single-center cohort from Turkey: a molecular surveillance study.BMC infectious diseases · 2026Article
- Strain-level transmission inference across multi-kingdom metagenomic data using TRACS.Nature microbiology · 2026Article
- Comparative genomic analyses ofmSystems · 2026Article
- Genomic characterization of extended-spectrum β-Lactamases (ESBLs)-producing Escherichia coli recovered from bloodstream infections in China.BMC microbiology · 2026Article
- Genomic islands and plasmid borne antimicrobial resistance genes drive the evolution of high-risk, ST-131 uropathogenic E. coli NS30.BMC genomics · 2025Article
- Origin and development of twoMicrobial genomics · 2025Article
- The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: methods and limitations.The Journal of antimicrobial chemotherapy · 2025Article
- A multi-isolate genomic approach identifies diverseMicrobial genomics · 2025Article
- A virulent escherichia coli O121-B2-ST131 strain causes hemorrhagic pneumonia in mink: evidence from pathogenicity and animal challenge experiments.BMC veterinary research · 2025Article
- Genomic epidemiology of a novelFrontiers in cellular and infection microbiology · 2025Article
- The complete genome sequence of five pre-2013 Escherichia coli sequence type (ST)1193 strains reveals insights into an emerging pathogen.Access microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 4 countries.
Funding
Abstract
Antibiotic resistance is a significant global public health concern. Uropathogenic Escherichia coli sequence type (ST)131, a widely prevalent multidrug-resistant clone, is frequently associated with bacteraemia. This study investigates third-generation cephalosporin resistance in bloodstream infections caused by E. coli ST131. From 2013-2014 blood culture surveillance in Wales, 142 E. coli ST131 genomes were studied alongside global data. All three major ST131 clades were represented across Wales, with clade C/H30 predominant (n = 102/142, 71.8%). Consistent with global findings, Welsh strains of clade C/H30 contain β-lactamase genes from the bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.